Xcout Intel
ImmunOs Therapeutics AG
ImmunOs Therapeutics AG is a biotechnology company that develops treatments for cancer and inflammatory diseases by harnessing the human immune system. The company focuses on immuno-oncology and autoimmune therapies through a dedicated drug pipeline.
Subscribe to see ImmunOs Therapeutics AG’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ImmunOs Therapeutics AG at a glance
ImmunOs Therapeutics AG is a biotechnology company headquartered in Switzerland. It has raised at least $85M across the 3 funding rounds on record, 2 of them with a disclosed amount. Its most recent funding round, Series C, raised $11M in September 2024. Xcout tracks 5 named people at ImmunOs Therapeutics AG, including Daniel Vasella (VICE CHAIRMAN).
ImmunOs Therapeutics AG leadership
- Daniel VasellaVICE CHAIRMAN
- Reinhard Ambros, PhDCHAIRMAN OF THE BOARD
- Christoph Kocher, PhDDirector
- Markus Hosang, PhDDirector
- Steve Tregay, PhDDirector
ImmunOs Therapeutics AG funding rounds
At least $85M raised across the 3 rounds on record (2 with a disclosed amount). Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series C | $11M | — | |
| Series B | $74M | 10 named | |
| — | Undisclosed | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Investors
ImmunOs Therapeutics AG competitors
A few of ImmunOs Therapeutics AG's closest competitors — see the full list of competitors and alternatives →
OSE Immunotherapeutics is a clinical-stage biotechnology company that develops innovative immunotherapies for immune activation and regulation in immuno-oncology and immuno-inflammation. The company utilizes proprietary research platforms and a portfolio of clinical-stage assets to provide therapeutic options for patients.
ImCheck Therapeutics designs and develops next-generation immunotherapeutic antibodies focused on modulating the immune system through the butyrophilin and butyrophilin-like superfamily of checkpoint molecules. The company's pipeline targets treatments for cancer, infectious disease, and autoimmune disease.
iOmx Therapeutics AG is a biopharmaceutical company located in Martinsried near Munich, Germany, dedicated to discovering and developing next-generation targeted cancer immunotherapies.
T3 Pharmaceuticals AG is a biotechnology company that develops a proprietary technology platform utilizing bacteria to deliver targeted therapies. The company focuses on advancing a pipeline of Immuno-Oncology products designed to treat cancer patients.
Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.
Numab Therapeutics is a Swiss biotechnology company developing multispecific antibody-based medicines that modulate immune-cell interactions. Its programs target serious diseases including cancer and immune-mediated or inflammatory disorders, serving patients through development and potential partnerships with pharmaceutical companies.
Get ImmunOs Therapeutics AG's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on ImmunOs Therapeutics AG in Xcout Intel
- 5 named people with titles, LinkedIn and board committees
- 3 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access